Amdocs Limited (NASDAQ:DOX – Free Report) – Analysts at Zacks Research decreased their Q1 2025 EPS estimates for shares of Amdocs in a report issued on Wednesday, October 16th. Zacks Research analyst R. Department now anticipates that the technology company will post earnings of $1.52 per share for the quarter, down from their previous forecast of $1.53. The consensus estimate for Amdocs’ current full-year earnings is $5.67 per share. Zacks Research also issued estimates for Amdocs’ Q2 2025 earnings at $1.55 EPS and Q1 2026 earnings at $1.65 EPS.
Amdocs (NASDAQ:DOX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The technology company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.02. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Amdocs had a net margin of 10.21% and a return on equity of 17.89%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.41 earnings per share.
View Our Latest Analysis on DOX
Amdocs Stock Performance
NASDAQ:DOX opened at $89.66 on Thursday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.24 and a current ratio of 1.24. The company has a fifty day moving average of $86.12 and a two-hundred day moving average of $83.52. The stock has a market capitalization of $10.54 billion, a PE ratio of 20.15, a P/E/G ratio of 1.42 and a beta of 0.74. Amdocs has a fifty-two week low of $74.41 and a fifty-two week high of $94.04.
Institutional Investors Weigh In On Amdocs
Large investors have recently modified their holdings of the business. Norwood Financial Corp purchased a new stake in shares of Amdocs during the first quarter worth $33,000. Central Pacific Bank Trust Division purchased a new stake in shares of Amdocs in the first quarter valued at about $53,000. Riverview Trust Co purchased a new stake in shares of Amdocs in the first quarter valued at about $55,000. GAMMA Investing LLC grew its holdings in shares of Amdocs by 115.1% in the third quarter. GAMMA Investing LLC now owns 800 shares of the technology company’s stock valued at $70,000 after purchasing an additional 428 shares during the period. Finally, American National Bank purchased a new stake in shares of Amdocs in the second quarter valued at about $76,000. Hedge funds and other institutional investors own 92.02% of the company’s stock.
Amdocs Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.479 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.14%. The ex-dividend date is Monday, September 30th. Amdocs’s payout ratio is 42.92%.
About Amdocs
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
See Also
- Five stocks we like better than Amdocs
- Why Invest in High-Yield Dividend Stocks?
- Why Buffett Loves Occidental Stock And What It Means for Chevron
- Stock Analyst Ratings and Canadian Analyst Ratings
- UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
- What Are the FAANG Stocks and Are They Good Investments?
- Why Alphabet Could Rally 30% Before Christmas
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.